Large-scale testing (Phase 3)Study completedNCT02394795What this trial is testingPanitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCWho this might be right forColorectal Cancer Takeda 823
Not applicableStudy completedNCT03750175What this trial is testingOPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -Who this might be right forColorectal Cancer MetastaticCirculating Tumor DNAKRAS Gene Mutation+3 more Karen-Lise Garm Spindler 49
Not applicableAvailableNCT07083479What this trial is testingExpanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal AdenocarcinomaWho this might be right forPancreatic Ductal AdenocarcinomaKRAS G12DKRAS G12V+12 more Elicio Therapeutics
Early research (Phase 1)Ended earlyNCT06270082What this trial is testingStudy of IK-595 in RAS- or RAF-altered Advanced TumorsWho this might be right forSolid Tumor, AdultColorectal CancerPancreatic Cancer+7 more Ikena Oncology 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864What this trial is testingELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsWho this might be right forPancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more Elicio Therapeutics 158
Early research (Phase 1)Study completedNCT02906059What this trial is testingStudy of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer NYU Langone Health 7
Not applicableLooking for participantsNCT04151342What this trial is testingCAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)Who this might be right forCancerMalignancies MultipleMalignant Solid Tumor+7 more University Health Network, Toronto 5,500
Early research (Phase 1)Study completedNCT03118817What this trial is testingExpansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid CancersWho this might be right forSolid Tumor Hanmi Pharmaceutical Company Limited 65
Testing effectiveness (Phase 2)Looking for participantsNCT05841550What this trial is testingThe TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple MyelomaWho this might be right forMultiple MyelomaSmoldering Multiple Myeloma Oslo University Hospital 20
Not applicableAvailableNCT04566393What this trial is testingExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesWho this might be right forPancreatic CancerSmall Bowel CancerColorectal Cancer+18 more xCures
Not applicableStudy completedNCT02827565What this trial is testingTechnical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer Institut de Cancérologie de Lorraine 30
Early research (Phase 1)Ended earlyNCT04249843What this trial is testingStudy of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory TumorsWho this might be right forSolid TumorB-Raf Mutation-Related Tumors MapKure, LLC 109
Early research (Phase 1)Study completedNCT03597581What this trial is testingRGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal CancerWho this might be right forGastrointestinal CancerGastrointestinal NeoplasmsColorectal Cancer+7 more Inspirna, Inc. 89
Early research (Phase 1)Looking for participantsNCT06096974What this trial is testingPan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRASWho this might be right forAdvanced Solid Tumors Shanghai YingLi Pharmaceutical Co. Ltd. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06106308What this trial is testingStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationWho this might be right forMetastatic Colorectal CancerCRCKRAS/NRAS Mutation Cardiff Oncology 113
Testing effectiveness (Phase 2)Looking for participantsNCT05786924What this trial is testingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesWho this might be right forNon-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more Institut de Recherches Internationales Servier 554
Large-scale testing (Phase 3)Looking for participantsNCT06881784What this trial is testingStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Who this might be right forNSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more Revolution Medicines, Inc. 420
Testing effectiveness (Phase 2)Looking for participantsNCT06229340What this trial is testingLeflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS MutationsWho this might be right forRAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more N.N. Petrov National Medical Research Center of Oncology 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945What this trial is testingRegorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerWho this might be right forBRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more Academic and Community Cancer Research United 22
Not applicableStudy completedNCT02751177What this trial is testingDetection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal CancerWho this might be right forColorectal Cancer Metastatic Institut de Cancérologie de Lorraine 236